Search
01/06/2024
Predictive gene signature for trabectedin efficacy in advanced soft-tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study
Moura, DS, Varela, JAC, Alvarez, R, Pujol, CA, Izquierdo, F, Ramos, R, Ortega, L, Martin-Davila, F, Leon, NH, Romagosa, C, Vaz-Salgado, MA, Lavernia, J, Bague, S, Mayodormo-Aranda, E, Mondaza-Hernandez, JL, Renshaw-Calderon, M, Hindi, N, Morales, CV, Martínez-Trufero, J, Broto, JM. Predictive gene signature for trabectedin efficacy in advanced soft-tissue sarcoma: A Spanish group for research in sarcoma (GEIS) study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).
01/06/2024
Soluble low- density lipoprotein receptor-related protein 1 as a marker of carotid plaque inflammation in patients with a recent ischemic stroke
Rodríguez, EG, Renom, PC, Puíg, N, León, AF, Simón, AA, Amaro, AB, Solé, A, Vilades, D, Quesada, JLS, Fábregas, JM, Xarrié, EJ, Benitez, S, Cortés, VL. Soluble low- density lipoprotein receptor-related protein 1 as a marker of carotid plaque inflammation in patients with a recent ischemic stroke. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION. 2024; 54DOI:. PMID:. IF:3.600(Q1/2D).
01/06/2024
Clinical Validation of Digital Healthcare Solutions: State of the Art, Challenges and Opportunities
Gomis-Pastor, M, Berdún, J, Borrás-Santos, A, López, AD, Rama, BFM, García-Esquirol, O, Gratacòs, M, Rodríguez, GDO, Cruz, RP, Real, J, Ferrer, JBI, Comella, A. Clinical Validation of Digital Healthcare Solutions: State of the Art, Challenges and Opportunities. Healthcare. 2024; 12(11)DOI:10.3390/healthcare12111057. PMID:38891132. IF:2.700(Q2/4D).
01/06/2024
First-line pembrolizumab for lung cancer in a Spanish real-world study.
Burgos, A, Calleja, T, Ibáñez, C, Valencia, CM, Orallo, C, Titos, JC, Conde, D, Diaz, S, Matilla, B, Lizeaga, G, Sánchez, C, Pozo, JFM, Jimenez, S, Jiménez, I, Díez, R, Garrido, M, Larrosa, M, Martinez, MJ, Moreno, E, Campelo, RG. First-line pembrolizumab for lung cancer in a Spanish real-world study.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(16)DOI:. PMID:. IF:41.900(Q1/1D).